Adverum Biotechnologies, Inc. (ADVM)
Dec 9, 2025 - ADVM was delisted (reason: acquired by LLY)
4.360
+0.100 (2.35%)
Inactive · Last trade price on Dec 8, 2025
Adverum Biotechnologies Revenue
In the year 2024, Adverum Biotechnologies had annual revenue of $1.00M, down -72.22%.
Revenue (ttm)
$1.00M
Revenue Growth
-72.22%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
155
Market Cap
96.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.00M | -2.60M | -72.22% |
| Dec 31, 2023 | 3.60M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 7.50M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 250.00K | -1.36M | -84.49% |
| Dec 31, 2018 | 1.61M | -237.00K | -12.82% |
| Dec 31, 2017 | 1.85M | 394.00K | 27.08% |
| Dec 31, 2016 | 1.46M | -864.00K | -37.26% |
| Dec 31, 2015 | 2.32M | 1.75M | 305.42% |
| Dec 31, 2014 | 572.00K | 92.00K | 19.17% |
| Dec 31, 2013 | 480.00K | 450.00K | 1,500.00% |
| Dec 31, 2012 | 30.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionADVM News
- 7 days ago - Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition - PRNewsWire
- 15 days ago - Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly - GlobeNewsWire
- 7 weeks ago - Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM - Business Wire
- 7 weeks ago - Eli Lilly to buy gene therapy developer Adverum in about $262 million deal - Reuters
- 7 weeks ago - Lilly to Acquire Adverum Biotechnologies - PRNewsWire
- 3 months ago - Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration - GlobeNewsWire
- 3 months ago - Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - GlobeNewsWire